A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia
Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinical...
Gespeichert in:
Veröffentlicht in: | Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2015-06, Vol.15 (6), p.377-383 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinically acceptable dose. This busulfan AUC target might be associated with improved relapse-free survival. |
---|---|
ISSN: | 2152-2650 2152-2669 |
DOI: | 10.1016/j.clml.2015.02.016 |